Erythrocytosis and thrombotic events in kidney transplant recipients prescribed a sodium glucose cotransport‐2 inhibitor
Clinical Transplantation · 2023
DOI: 10.1111/ctr.15013 ↗At a glance
Journal article in Clinical Transplantation, 2023. Written by Maia Gill and 7 co-authors. Institution: University of British Columbia, Division of Nephrology, Kidney Transplant program, Vancouver, Canada. Major MEDLINE topics: Polycythemia, Kidney Transplantation, Thrombosis, Diabetes Mellitus, Type 2. Cited 2 times so far (Crossref); 28 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Introduction
The safety and efficacy of sodium glucose cotransport‐2 inhibitors (SGLT2i) in kidney transplant recipients remains uncertain. Transplant recipients may be at risk of thrombosis because of post‐transplant erythrocytosis and SGLT2i are associated with an increase in hematocrit.
Methods
We determined SGLT2i use, the change in hematocrit and incidence of thrombotic events in kidney transplant recipients in 1700 prevalent patients in our center.
Results
Among the 42 patients treated with SGLT2i, the mean pre‐transplant hematocrit was 31%, and none of the patients had a hematocrit ≥50%. The mean percent change in hematocrit measured at an average of 53 days after initiation of an SGLT2i was 11% and four patients (10%) had a hematocrit ≥ 50%. The mean hematocrit measured 3 months after treatment was 42% and two patients (5%) had a hematocrit ≥50%. One patient had a cerebellar stroke 14 months post‐SGLT2i initiation when the hemoglobin was 173 grams/liter, and the hematocrit was 52%.
Conclusions
All patients had a sustained increase in hematocrit 3 months after SGLT2i treatment. Hematocrit ≥50% occurred in 10%, and one patient had a thrombotic event that may or may not have been related to an increase in hematocrit. Clinicians may consider monitoring for erythrocytosis after starting and SGLT2i in kidney transplant recipients.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- University of British Columbia, Division of Nephrology, Kidney Transplant program, Vancouver, Canada.
- University of British Columbia Faculty of Pharmaceutical Sciences, Vancouver, Canada.
- Providence Healthcare, Seattle, USA.
- Fraser Health, Surrey, Canada.
- Providence Health Research Institute, Seattle, USA.
ORCID profiles: Marianna Leung, Catherine Cheung, Olwyn Johnston
Cite
APA
Gill, M., Leung, M., Luo, C. Y., Cheung, C., Beauchesne, A., Chang, D., Lan, J., & Johnston, O. (2023). Erythrocytosis and thrombotic events in kidney transplant recipients prescribed a sodium glucose cotransport‐2 inhibitor. Clinical Transplantation. https://doi.org/10.1111/ctr.15013
Vancouver
Gill M, Leung M, Luo CY, Cheung C, Beauchesne A, Chang D, et al. Erythrocytosis and thrombotic events in kidney transplant recipients prescribed a sodium glucose cotransport‐2 inhibitor. Clinical Transplantation. 2023. doi:10.1111/ctr.15013
BibTeX
@article{Gill2023,
author = {Gill, Maia and Leung, Marianna and Luo, Cindy Y and Cheung, Catherine and Beauchesne, Arielle and Chang, Doris and Lan, James and Johnston, Olwyn},
title = {Erythrocytosis and thrombotic events in kidney transplant recipients prescribed a sodium glucose cotransport‐2 inhibitor},
journal = {Clinical Transplantation},
year = {2023},
doi = {10.1111/ctr.15013}
}
EUVIMED